Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
AVEO PHARMACEUTICALS, INC. (AVEO) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/19/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Amended and Restated Certificate of Incorporation of AVEO Pharmaceuticals, Inc",
"Amended and Restated Bylaws of AVEO Pharmaceuticals, Inc",
"LG Chem Completes Acquisition of AVEO Oncology"
01/18/2023 8-K Quarterly results
01/05/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/02/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2022 Financial Results – Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® U.S. Net Product Revenue –"
10/18/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among AVEO Pharmaceuticals, Inc., LG Chem, Ltd. and Acacia Acquisition Sub, Inc",
"Second Amended and Restated Bylaws of AVEO Pharmaceuticals, Inc., as amended",
"LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash"
08/09/2022 8-K Investor presentation
Docs: "Cautionary Note Regarding Forward-Looking Statements This"
08/04/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/08/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "EXECUTION 30 WINTER STREET OFFICE LEASE 2 OFFICE LEASE BETWEEN TFC 30 WINTER LLC,"
03/14/2022 8-K Investor presentation
Docs: "Cautionary Note Regarding Forward-Looking Statements This"
03/14/2022 8-K Quarterly results
Docs: "AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results – Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® U.S. Net Product Revenue of $38.9 Million since March 22, 2021 –"
12/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2021 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update"
08/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Termination, Separation and Release of Claims Agreement, by and between AVEO Pharmaceuticals, Inc. and Michael Needle, M.D"
08/05/2021 8-K Quarterly results
07/16/2021 8-K Quarterly results
06/09/2021 8-K/A Quarterly results
06/09/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
02/08/2021 8-K/A Quarterly results
02/02/2021 8-K Quarterly results
01/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation and Release of Claims Agreement, by and between AVEO Pharmaceuticals, Inc. and Karuna Rubin"
01/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/12/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update - U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 –"
09/08/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy